{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:33:36Z","timestamp":1786980816009,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07649-y","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T03:41:54Z","timestamp":1731728514000},"page":"1275-1287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-9688","authenticated-orcid":false,"given":"Kehinde S.","family":"Olaniyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Areloegbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olabimpe C.","family":"Badejogbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac O.","family":"Ajadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B.","family":"Ajadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"issue":"12","key":"7649_CR1","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841\u201355. https:\/\/doi.org\/10.1093\/humrep\/dew218.","journal-title":"Hum Reprod"},{"key":"7649_CR2","doi-asserted-by":"publisher","unstructured":"American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 194: polycystic ovary syndrome. Obstetrics and gynecology. 2018;131(6): 157\u201371 https:\/\/doi.org\/10.1097\/AOG.0000000000002656.","DOI":"10.1097\/AOG.0000000000002656"},{"issue":"7","key":"7649_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","volume":"30","author":"O Osibogun","year":"2020","unstructured":"Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399\u2013404. https:\/\/doi.org\/10.1016\/j.tcm.2019.08.010.","journal-title":"Trends Cardiovasc Med"},{"key":"7649_CR4","doi-asserted-by":"publisher","unstructured":"Purwar A, Nagpure S. Insulin resistance in polycystic ovarian syndrome. Cureus. 2022 Oct;14(10). https:\/\/doi.org\/10.7759\/cureus.30351.","DOI":"10.7759\/cureus.30351"},{"issue":"5","key":"7649_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.fertnstert.2022.03.009","volume":"117","author":"C Guan","year":"2022","unstructured":"Guan C, Zahid S, Minhas AS, et al. Polycystic ovary syndrome: a \u201crisk-enhancing\u201d factor for cardiovascular disease. Fertil Steril. 2022;117(5):924\u201335. https:\/\/doi.org\/10.1016\/j.fertnstert.2022.03.009.","journal-title":"Fertil Steril"},{"issue":"5","key":"7649_CR6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.fertnstert.2014.08.001","volume":"102","author":"NM Daan","year":"2014","unstructured":"Daan NM, Louwers YV, Koster MP, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014;102(5):1444\u201351. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.08.001.","journal-title":"Fertil Steril"},{"issue":"12","key":"7649_CR7","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41401-023-01128-0","volume":"44","author":"HY Ye","year":"2023","unstructured":"Ye HY, Song YL, Ye WT, et al. Serum granulosa cell-derived TNF-\u03b1 promotes inflammation and apoptosis of renal tubular cells and PCOS-related kidney injury through NF-\u03baB signaling. Acta Pharmacol Sin. 2023;44(12):2432\u201344. https:\/\/doi.org\/10.1038\/s41401-023-01128-0.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"7649_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1139\/cjpp-2022-0176","volume":"100","author":"MU Peter","year":"2022","unstructured":"Peter MU, Areloegbe SE, Akintayo CO, Oniyide AA, Aturamu A, Olaniyi KS. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX\/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model. Can J Physiol Pharmacol. 2022;100(9):890\u2013902. https:\/\/doi.org\/10.1139\/cjpp-2022-0176.","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"7649_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40360-023-00692-9","volume":"24","author":"AA Bashir","year":"2023","unstructured":"Bashir AA, Olaniyi KS. Butyrate alleviates renal inflammation and fibrosis in a rat model of polycystic ovarian syndrome by suppression of SDF-1. BMC Pharmacol Toxicol. 2023;24(1):48. https:\/\/doi.org\/10.1186\/s40360-023-00692-9.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"25","key":"7649_CR10","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.005.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7649_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/eht386.","journal-title":"Eur Heart J"},{"key":"7649_CR12","doi-asserted-by":"publisher","unstructured":"Collaborators GB. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017; https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"10075","key":"7649_CR13","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(16)32064-5.","journal-title":"Lancet"},{"issue":"4","key":"7649_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.mcna.2023.03.011","volume":"107","author":"W McCallum","year":"2023","unstructured":"McCallum W, Testani JM. Updates in cardiorenal syndrome. Med Clin North Am. 2023;107(4):763\u201380. https:\/\/doi.org\/10.1016\/j.mcna.2023.03.011.","journal-title":"Med Clin North Am"},{"issue":"3","key":"7649_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ccl.2019.04.001","volume":"37","author":"U Kumar","year":"2019","unstructured":"Kumar U, Wettersten N, Garimella PS. Cardiorenal syndrome: pathophysiology. Cardiol Clin. 2019;37(3):251\u201365. https:\/\/doi.org\/10.1016\/j.ccl.2019.04.001.","journal-title":"Cardiol Clin"},{"issue":"5","key":"7649_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/ndt\/gfq066","volume":"25","author":"SM Bagshaw","year":"2010","unstructured":"Bagshaw SM, Cruz DN, Aspromonte N, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant. 2010;25(5):1406\u201316. https:\/\/doi.org\/10.1093\/ndt\/gfq066.","journal-title":"Nephrol Dial Transplant"},{"key":"7649_CR17","doi-asserted-by":"publisher","unstructured":"Gargiulo R, Suhail F, Lerma EV. Cardiovascular disease and chronic kidney disease. Disease-a-month: DM. 2015;61(9):403\u201313. https:\/\/doi.org\/10.1016\/j.disamonth.2015.07.005.","DOI":"10.1016\/j.disamonth.2015.07.005"},{"issue":"9888","key":"7649_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)60687-X.","journal-title":"The Lancet"},{"key":"7649_CR19","doi-asserted-by":"publisher","unstructured":"Weiner DE, Sarnak MJ. Cardiac function and cardiovascular disease in chronic kidney disease. In National Kidney Foundation\u2019s Primer on Kidney Diseases 2018 (pp. 506\u2013514). Elsevier. https:\/\/doi.org\/10.1016\/B978-1-4160-5185-5.00059-6.","DOI":"10.1016\/B978-1-4160-5185-5.00059-6"},{"issue":"2","key":"7649_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ki.1990.44","volume":"37","author":"HH Radeke","year":"1990","unstructured":"Radeke HH, Meier B, Topley N, Fl\u00f6ge J, Habermehl GG, Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int. 1990;37(2):767\u201375. https:\/\/doi.org\/10.1038\/ki.1990.44.","journal-title":"Kidney Int"},{"issue":"2","key":"7649_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ki.1990.44","volume":"37","author":"HH Radeke","year":"1990","unstructured":"Radeke HH, Meier B, Topley N, Fl\u00f6ge J, Habermehl GG, Resch K. Interleukin 1-\u03b1 and tumor necrosis factor-\u03b1 induce oxygen radical production in mesangial cells. Kidney Int. 1990;37(2):767\u201375. https:\/\/doi.org\/10.1038\/ki.1990.44.","journal-title":"Kidney Int"},{"issue":"271","key":"7649_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2018.02.018","volume":"1","author":"A Bellasi","year":"2018","unstructured":"Bellasi A, Di Lullo L, Di Iorio B. Vascular inflammation: a call for a specific and sensitive biomarker? Atherosclerosis. 2018;1(271):235\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.02.018.","journal-title":"Atherosclerosis"},{"issue":"4","key":"7649_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000448749","volume":"2","author":"C Ronco","year":"2017","unstructured":"Ronco C, Di Lullo L. Cardiorenal syndrome in western countries: epidemiology, diagnosis and management approaches. Kidney diseases. 2017;2(4):151\u201363. https:\/\/doi.org\/10.1159\/000448749.","journal-title":"Kidney diseases"},{"issue":"3","key":"7649_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000351985","volume":"3","author":"J Omran","year":"2013","unstructured":"Omran J, Al-Dadah A, Dellsperger KC. Dyslipidemia in patients with chronic and end-stage kidney disease. Cardiorenal medicine. 2013;3(3):165\u201377. https:\/\/doi.org\/10.1159\/000351985.","journal-title":"Cardiorenal medicine"},{"key":"7649_CR25","doi-asserted-by":"publisher","unstructured":"R Rader DJ, Hovingh GK. HDL and cardiovascular disease. The Lancet. 2014 Aug 16;384(9943):618\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(14)61217-4.","DOI":"10.1016\/S0140-6736(14)61217-4"},{"issue":"60","key":"7649_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clinbiochem.2018.08.006","volume":"1","author":"M Miljkovic","year":"2018","unstructured":"Miljkovic M, Stefanovic A, Vekic J, et al. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. Clin Biochem. 2018;1(60):52\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.08.006.","journal-title":"Clin Biochem"},{"issue":"3","key":"7649_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/er.2003-0004","volume":"24","author":"RS Legro","year":"2003","unstructured":"Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24(3):302\u201312. https:\/\/doi.org\/10.1210\/er.2003-0004.","journal-title":"Endocr Rev"},{"issue":"132","key":"7649_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biochi.2016.10.010","volume":"1","author":"DA Chistiakov","year":"2017","unstructured":"Chistiakov DA, Melnichenko AA, Orekhov AN, Bobryshev YV. Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie. 2017;1(132):19\u201327. https:\/\/doi.org\/10.1016\/j.biochi.2016.10.010.","journal-title":"Biochimie"},{"issue":"1","key":"7649_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0014-5793(98)00064-7","volume":"423","author":"B Mackness","year":"1998","unstructured":"Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998;423(1):57\u201360. https:\/\/doi.org\/10.1016\/s0014-5793(98)00064-7.","journal-title":"FEBS Lett"},{"issue":"3","key":"7649_CR30","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1210\/jc.2004-0486","volume":"90","author":"G Ferretti","year":"2005","unstructured":"Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90(3):1728\u201333. https:\/\/doi.org\/10.1210\/jc.2004-0486.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7649_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/726048","volume":"2012","author":"A Gugliucci","year":"2012","unstructured":"Gugliucci A, Kotani K, Kimura S. Paraoxonase 1 in chronic kidney failure. Journal of Lipids. 2012;2012(1): 726048. https:\/\/doi.org\/10.1155\/2012\/726048.","journal-title":"Journal of Lipids"},{"issue":"1","key":"7649_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1161\/CIRCRESAHA.114.300935","volume":"114","author":"TF L\u00fcscher","year":"2014","unstructured":"L\u00fcscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114(1):171\u201382. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.300935.","journal-title":"Circ Res"},{"key":"7649_CR33","doi-asserted-by":"publisher","unstructured":"Gugliucci A, Kinugasa E, Kotani K, Caccavello R, Kimura S. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clinical chemistry and laboratory medicine. 2011 Jan 1;49(1):61\u20137. NAFLD and T2DM. Nat Rev Endocrinol.;15(5):261\u2013273. https:\/\/doi.org\/10.1515\/CCLM.2011.004.","DOI":"10.1515\/CCLM.2011.004"},{"issue":"6","key":"7649_CR34","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh A, De Vadder F, Kovatcheva-Datchary P, B\u00e4ckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332\u201345. https:\/\/doi.org\/10.1016\/j.cell.2016.05.041.","journal-title":"Cell"},{"issue":"1","key":"7649_CR35","doi-asserted-by":"publisher","first-page":"10277","DOI":"10.1038\/s41598-017-10471-2","volume":"7","author":"M Bhat","year":"2017","unstructured":"Bhat M, Pasini E, Copeland J, Angeli M, Husain S, Kumar D, et al. Impact of immunosuppression on the metagenomic composition of the intestinal microbiome: a systems biology approach to post-transplant diabetes. Sci Rep. 2017;7(1):10277. https:\/\/doi.org\/10.1038\/s41598-017-10471-2.","journal-title":"Sci Rep"},{"key":"7649_CR36","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00210-019-01679-2","volume":"392","author":"C Badejogbin","year":"2019","unstructured":"Badejogbin C, Areola DE, Olaniyi KS, Adeyanju OA, Adeosun IO. Sodium butyrate recovers high-fat diet-fed female Wistar rats from glucose dysmetabolism and uric acid-associated cardiac tissue damage. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:1411\u20139. https:\/\/doi.org\/10.1007\/s00210-019-01679-2.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7268","key":"7649_CR37","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/nature08530","volume":"461","author":"KM Maslowski","year":"2009","unstructured":"Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461(7268):1282\u20136. https:\/\/doi.org\/10.1038\/nature08530.","journal-title":"Nature"},{"issue":"02","key":"7649_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1055\/a-1081-2036","volume":"80","author":"X Zhao","year":"2020","unstructured":"Zhao X, Jiang Y, Xi H, Chen L, Feng X. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): a review. Geburtshilfe Frauenheilkd. 2020;80(02):161\u201371. https:\/\/doi.org\/10.1055\/a-1081-2036.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"7649_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/09513590.2016.1236078","volume":"33","author":"F Fruzzetti","year":"2017","unstructured":"Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017;33(1):39\u201342. https:\/\/doi.org\/10.1080\/09513590.2016.1236078.","journal-title":"Gynecol Endocrinol"},{"key":"7649_CR40","doi-asserted-by":"publisher","unstructured":"Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics: targets and therapy. 2011;11:71\u201386. https:\/\/doi.org\/10.2147\/BTT.S19099.","DOI":"10.2147\/BTT.S19099"},{"issue":"8","key":"7649_CR41","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.3390\/nu13082792","volume":"13","author":"YP Hsiao","year":"2021","unstructured":"Hsiao YP, Chen HL, Tsai JN, et al. Administration of Lactobacillus reuteri combined with Clostridium butyricum attenuates cisplatin-induced renal damage by gut microbiota reconstitution, increasing butyric acid production, and suppressing renal inflammation. Nutrients. 2021;13(8):2792. https:\/\/doi.org\/10.3390\/nu13082792.","journal-title":"Nutrients"},{"issue":"1","key":"7649_CR42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13148-023-01487-9","volume":"15","author":"K Liu","year":"2023","unstructured":"Liu K, He X, Huang J, et al. Short-chain fatty acid-butyric acid ameliorates granulosa cells inflammation through regulating METTL3-mediated N6-methyladenosine modification of FOSL2 in polycystic ovarian syndrome. Clin Epigenetics. 2023;15(1):86. https:\/\/doi.org\/10.1186\/s13148-023-01487-9.","journal-title":"Clin Epigenetics"},{"issue":"7","key":"7649_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/B978-0-7020-4226-3.00010-X","volume":"1","author":"JD Bancroft","year":"2012","unstructured":"Bancroft JD, Layton C. The hematoxylins and eosin. Bancroft\u2019s theory and practice of histological techniques. 2012;1(7):173\u201386. https:\/\/doi.org\/10.1016\/B978-0-7020-4226-3.00010-X.","journal-title":"Bancroft\u2019s theory and practice of histological techniques"},{"issue":"7","key":"7649_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","volume":"12","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12(7):324\u201332. https:\/\/doi.org\/10.1016\/j.molmed.2006.05.006.","journal-title":"Trends Mol Med"},{"issue":"1","key":"7649_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1429.005","volume":"1135","author":"SK Blank","year":"2008","unstructured":"Blank SK, Helm KD, McCartney CR, Marshall JC. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci. 2008;1135(1):76\u201384. https:\/\/doi.org\/10.1196\/annals.1429.005.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"7649_CR46","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1093\/humrep\/dev195","volume":"30","author":"NM Daan","year":"2015","unstructured":"Daan NM, Jaspers L, Koster MP, et al. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features. Hum Reprod. 2015;30(10):2376\u201386. https:\/\/doi.org\/10.1093\/humrep\/dev195.","journal-title":"Hum Reprod"},{"issue":"3","key":"7649_CR47","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.fertnstert.2016.12.017","volume":"107","author":"P Pinola","year":"2017","unstructured":"Pinola P, Puukka K, Piltonen TT, et al. Normo-and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertil Steril. 2017;107(3):788\u201395. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.12.017.","journal-title":"Fertil Steril"},{"issue":"8","key":"7649_CR48","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/bph.14933","volume":"177","author":"Y Du","year":"2020","unstructured":"Du Y, Li X, Su C, et al. Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice. Br J Pharmacol. 2020;177(8):1754\u201372. https:\/\/doi.org\/10.1111\/bph.14933.","journal-title":"Br J Pharmacol"},{"issue":"15","key":"7649_CR49","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/nu16152454","volume":"16","author":"F Fogacci","year":"2024","unstructured":"Fogacci F, Giovannini M, Di Micoli V, Grandi E, Borghi C, Cicero AF. Effect of supplementation of a butyrate-based formula in individuals with liver steatosis and metabolic syndrome: a randomized double-blind placebo-controlled clinical trial. Nutrients. 2024;16(15):2454. https:\/\/doi.org\/10.3390\/nu16152454.","journal-title":"Nutrients"},{"issue":"3","key":"7649_CR50","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.yjmcc.2009.06.021","volume":"48","author":"L Maya","year":"2010","unstructured":"Maya L, Villarreal FJ. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol. 2010;48(3):524\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.06.021.","journal-title":"J Mol Cell Cardiol"},{"issue":"7268","key":"7649_CR51","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/nature08530","volume":"461","author":"KM Maslowski","year":"2009","unstructured":"Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461(7268):1282\u20136. https:\/\/doi.org\/10.1038\/nature08530.","journal-title":"Nature"},{"issue":"24","key":"7649_CR52","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1161\/CIRCULATIONAHA.123.065827","volume":"148","author":"L Gao","year":"2023","unstructured":"Gao L, Zhao Y, Wu H, et al. Polycystic ovary syndrome fuels cardiovascular inflammation and aggravates ischemic cardiac injury. Circulation. 2023;148(24):1958\u201373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065827.","journal-title":"Circulation"},{"issue":"8","key":"7649_CR53","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.hlc.2016.02.022","volume":"25","author":"B Giam","year":"2016","unstructured":"Giam B, Kaye DM, Rajapakse NW. Role of renal oxidative stress in the pathogenesis of the cardiorenal syndrome. Heart Lung Circ. 2016;25(8):874\u201380. https:\/\/doi.org\/10.1016\/j.hlc.2016.02.022.","journal-title":"Heart Lung Circ"},{"issue":"120","key":"7649_CR54","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.freeradbiomed.2018.03.053","volume":"20","author":"K Iwata","year":"2018","unstructured":"Iwata K, Matsuno K, Murata A, et al. Up-regulation of NOX1\/NADPH oxidase following drug-induced myocardial injury promotes cardiac dysfunction and fibrosis. Free Radical Biol Med. 2018;20(120):277\u201388. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.03.053.","journal-title":"Free Radical Biol Med"},{"issue":"300","key":"7649_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120560","volume":"1","author":"KS Olaniyi","year":"2022","unstructured":"Olaniyi KS, Areloegbe SE. Suppression of PCSK9\/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome. Life Sci. 2022;1(300): 120560. https:\/\/doi.org\/10.1016\/j.lfs.2022.120560.","journal-title":"Life Sci"},{"issue":"1","key":"7649_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/JOE-16-0322","volume":"232","author":"W Dong","year":"2017","unstructured":"Dong W, Jia Y, Liu X, et al. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. J Endocrinol. 2017;232(1):71\u201383. https:\/\/doi.org\/10.1530\/JOE-16-0322.","journal-title":"J Endocrinol"},{"key":"7649_CR57","doi-asserted-by":"publisher","unstructured":"Sluman C, Gudka PM, McCormick K. Acute kidney Injury: pre-renal, intra-renal and post-renal. Ren Med Clin Pharm. 2020:23\u201344. https:\/\/doi.org\/10.1007\/978-3-030-37655-0_3.","DOI":"10.1007\/978-3-030-37655-0_3"},{"issue":"1","key":"7649_CR58","doi-asserted-by":"publisher","first-page":"7643322","DOI":"10.1155\/2022\/7643322","volume":"2022","author":"T Zhou","year":"2022","unstructured":"Zhou T, Xu H, Cheng X, et al. Sodium butyrate attenuates diabetic kidney disease partially via histone butyrylation modification. Mediators Inflamm. 2022;2022(1):7643322. https:\/\/doi.org\/10.1155\/2022\/7643322.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"7649_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.dsx.2020.01.002","volume":"14","author":"J Heshmati","year":"2020","unstructured":"Heshmati J, Golab F, Morvaridzadeh M, et al. The effects of curcumin supplementation on oxidative stress, sirtuin-1 and peroxisome proliferator activated receptor \u03b3 coactivator 1\u03b1 gene expression in polycystic ovarian syndrome (PCOS) patients: a randomized placebo-controlled clinical trial. Diabetes Metab Syndr. 2020;14(2):77\u201382. https:\/\/doi.org\/10.1016\/j.dsx.2020.01.002.","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"7649_CR60","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41419-021-03693-w","volume":"12","author":"HM Chang","year":"2021","unstructured":"Chang HM, Peng KY, Chan CK, et al. FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1\/CXCR4 signaling. Cell Death Dis. 2021;12(5):409. https:\/\/doi.org\/10.1038\/s41419-021-03693-w.","journal-title":"Cell Death Dis"},{"issue":"1","key":"7649_CR61","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.1038\/s41467-023-43167-5","volume":"14","author":"HC Chen","year":"2023","unstructured":"Chen HC, Liu YW, Chang KC, et al. Gut butyrate-producers confer post-infarction cardiac protection. Nat Commun. 2023;14(1):7249. https:\/\/doi.org\/10.1038\/s41467-023-43167-5.","journal-title":"Nat Commun"},{"issue":"3","key":"7649_CR62","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1600-0412.2011.01337.x","volume":"91","author":"G Baskol","year":"2012","unstructured":"Baskol G, Aygen E, Erdem F, et al. Assessment of paraoxonase 1, xanthine oxidase and glutathione peroxidase activities, nitric oxide and thiol levels in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2012;91(3):326\u201330. https:\/\/doi.org\/10.1111\/j.1600-0412.2011.01337.x.","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07649-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:01:16Z","timestamp":1766127676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7649"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07649-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"7 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in line with the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals. Experimental protocol approval was obtained from the Independent Ethical Review Board of Afe Babalola University (Ado-Ekiti, Nigeria) with the approval number ABUADERC\/10D\/2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}